Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report

Hongchan Zhang, Linqi Li, Susu Zhao, Hao Wu, Jianwei Zhu

Open source

DOI
10.3389/fimmu.2026.1906365
Published
2026-08-24
Container
Frontiers in Immunology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1906365,
  title = {Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report},
  author = {Hongchan Zhang and Linqi Li and Susu Zhao and Hao Wu and Jianwei Zhu},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1906365},
  url = {https://doi.org/10.3389/fimmu.2026.1906365}
}

RIS

TY  - JOUR
TI  - Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report
AU  - Hongchan Zhang
AU  - Linqi Li
AU  - Susu Zhao
AU  - Hao Wu
AU  - Jianwei Zhu
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1906365
UR  - https://doi.org/10.3389/fimmu.2026.1906365
ER  - 

APA

Zhang, H., Li, L., Zhao, S., Wu, H., & Zhu, J. (2026). Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1906365

Source records